Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. - Wikidata - wikimedia - TriplyDB

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

http://www.wikidata.org/entity/Q41974388

about

Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer.Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.Tumor regulation of the tissue environment in the liver.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.The Heterocellular Emergence of Colorectal Cancer Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.Effective combinatorial immunotherapy for castration-resistant prostate cancer Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ.Targeting iNOS to increase efficacy of immunotherapies.Immunotherapy for Breast Cancer: What Are We Missing?The PI3K Pathway in Human Disease.Antiangiogenic therapy and immune checkpoint blockade go hand in hand.Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.The role of PI3Kγ in metabolism and macrophage activation.A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells.Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.Trial watch: Immune checkpoint blockers for cancer therapy.Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.Host STING-dependent MDSC mobilization drives extrinsic radiation resistance.Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.Nanomaterials for cancer immunotherapy.A drug development perspective on targeting tumor-associated myeloid cells.Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.Characterization of cluster of differentiation 47 expression and its potential as a therapeutic target in esophageal squamous cell cancer.Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer.Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners.Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas.Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma.[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.

P2860

Q34555169-C75495F2-DCEA-46EB-87DC-7389ECDE9277 Q37739485-60868A20-A187-4AAF-8D94-C57951074B91 Q38646993-A7C466E2-5E05-4ED1-B93F-10EB8B9AC35D Q39123136-F391C2CC-5A53-4689-9D9B-AD1A3C3E5F08 Q39130451-DCE7336A-1BD3-4FEB-BA93-CD04522E158C Q39152114-84882095-CC22-4914-811E-7C74DEDA92F1 Q39168810-BC634130-8669-4211-8CE3-9A4957E806C7 Q39204274-D0CD38C8-5771-48B6-8FD6-2E0460264280 Q41369903-2269DFFB-29CF-41F2-A49A-DE83496B8446 Q41716558-5E8D4B0A-BBFC-4496-B538-DA2B58119C08 Q42378867-30ECCD5F-1117-4B3E-A4F7-01A7AD4D5222 Q43024830-34F7A602-4395-4B3D-9375-625451FB42FA Q44668850-F31823E3-0E90-49B8-9435-6191F3E1325D Q46546002-74B6B7F6-AC56-4DBD-9585-2C6D64E1DFDA Q47121351-FD487DB2-B37E-4CCA-A54A-01CB5392349B Q47135020-A1548C14-0C5B-484B-9530-EF62C156DB26 Q47148314-1E45F893-3AC2-47EA-BD6D-8FA35B75B0E5 Q47207633-10F13DA4-7164-4FB0-BD4A-43088DFFC034 Q47236265-6AD1E4EA-FA7C-4418-B24E-7139A24A6BFF Q47325431-F3ADA995-3CFA-463E-A858-230FDC62421F Q47381391-2E43B48A-75E0-4278-A452-E21883AC8667 Q47388561-04DBA8EC-17BE-45F8-8A7C-F1731AA2880E Q47393365-84B53913-F7FB-4280-9A05-91197EF55790 Q47651773-5791B911-C4C7-4585-8EB8-5285C1AE9212 Q47936526-D3F8BADC-1AA2-4943-ACD7-07044536886C Q48245206-A2E734B8-AB52-4BD8-8D14-C554FC915A3C Q48293607-DAC1D58B-F209-4022-A6C0-6136E7754D4C Q48308089-2078D595-060D-4A51-BA78-39C518F093E7 Q48646732-3C8719BF-47E7-447A-BD35-C1DD5A388D7E Q48652546-EEFD35E2-6094-40DA-AFC8-150F758FF16A Q49295345-F7BB52BC-0708-4DFE-9734-9C3D7F99B0AF Q49334850-3600963B-BD1A-41A5-A1CC-4B18B5D9C54D Q49544289-59A17738-940A-4F3A-8EC6-A92DEB9F6225 Q49805542-63ABB2C7-3028-46BC-9CE1-6ED76F41E7A1 Q49865931-55407E23-17BE-4315-BC41-4072A318BFA7 Q49887083-778EA95E-7884-43C1-8D91-0A64D574F705 Q50034111-F9B1AE0B-402A-4961-9919-E1B67D8D88BB Q50045161-D7FE71AC-878A-431E-BC77-E61CD56B50C0 Q50046798-30E0BB87-5B2A-4D1C-BDC1-26CD42808B7F Q51079342-68BF88BB-80A4-4A8F-978C-43A2F5417F3F

P2860

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

http://www.wikidata.org/entity/Q41974388

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

@en

type

label

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

@en

prefLabel

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

@en

P1433

Q41974388-98F390EF-3694-495C-936E-AC1C235442BD

P1476

Q41974388-FCD0873C-FAB9-45E8-8179-C3A7CC010EB2

P2093

Q41974388-0B0917C2-9FD1-4A8F-8ACD-C1D2ACA2147F

Q41974388-12007A3E-64DA-4E60-B6DE-CCD96269657B

Q41974388-1E75E227-8F40-4CF6-931B-4BA679BC339D

Q41974388-3ACE4202-AD73-4190-BF43-442B5A9DCD9F

Q41974388-3E76FCB1-D3F7-4D05-8035-C891C73365D5

Q41974388-4738DC96-0D14-4246-A7EE-E7CC60CA2D8B

Q41974388-478660CB-B2AB-497C-A6F6-72727BF3ABFC

Q41974388-4BCCB4B2-B76A-49D6-A5B4-F2B02265FD43

Q41974388-4ED3CE15-D960-4061-9E8E-C840E874D23C

Q41974388-52D1901D-C9D6-4127-8BFB-C3FAF95BF15B

P2860

Q41974388-00B332C8-B31C-45BC-841D-9C5A655B1BE2

Q41974388-019E4296-E15E-43C8-893A-DB13029D6036

Q41974388-1E6F0987-C258-4AD5-9D05-C2FFC1B46B70

Q41974388-28B2A3DD-B98B-47B4-A8B6-AECB7E3CA9C9

Q41974388-2C206B29-137A-4603-83AB-D516600FEB70

Q41974388-3EAC2A2D-2FAC-4271-8021-EA4B155ED0BD

Q41974388-44634464-DD43-4576-8972-461E49E9F2B3

Q41974388-52DCCB1A-450F-4B8E-A849-A6FB6D6C7EEE

Q41974388-6BB6C49B-C5AA-444E-A11E-8C75533765A6

Q41974388-7AFF41E2-839D-4FC1-AA34-F4AA7A1D0EBF

P2888

Q41974388-DBEA6C17-5CB2-4829-83F5-9B651D90389B

P304

Q41974388-5356E0EB-3CD3-4F7C-852B-8CBF4FA0A102

P31

Q41974388-ABFEBAA2-5A61-4497-B76A-E1F15521270F

P356

Q41974388-1D74D72D-9116-4ACF-AA28-11C2EEEDA863

P407

Q41974388-83B4CC56-C22F-4B4F-A204-E52C2F90346E

P433

Q41974388-E800DABC-439A-435D-925F-753E2AF8711D

P478

Q41974388-2E96B361-F66C-422E-A26E-62AD3DBB6827

P50

Q41974388-B8FC4F89-5D27-4A12-B628-00CB429B610E

P577

Q41974388-185A2553-C316-46A1-9ED4-5781AC1461AE

P6179

Q41974388-F09CC04B-E3B5-469A-8C8B-143D618C26FD

P698

Q41974388-A0253DDB-E795-4CB6-8B47-C1A498A6FA8A

P932

Q41974388-FD7B828E-2862-4207-99CD-9D2AD8817D5E

P356

P1433

P1476

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

@en

P2093

Cailian Liu

http://www.w3.org/2001/XMLSchema#string

Daniel Hirschhorn Cymerman

http://www.w3.org/2001/XMLSchema#string

David Winkler

http://www.w3.org/2001/XMLSchema#string

Howard Stern

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Jeffery L Kutok

http://www.w3.org/2001/XMLSchema#string

Jennifer Proctor

http://www.w3.org/2001/XMLSchema#string

Jeremy Tchaicha

http://www.w3.org/2001/XMLSchema#string

John Soglia

http://www.w3.org/2001/XMLSchema#string

Julian Adams

http://www.w3.org/2001/XMLSchema#string

P2860

Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Innate and adaptive immune cells in the tumor microenvironment

Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

PI3Kγ is a molecular switch that controls immune suppression

Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation.

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment

P2888

P304

443-447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE20554

http://www.w3.org/2001/XMLSchema#string

P407

P433

7629

http://www.w3.org/2001/XMLSchema#string

P478

539

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1008620058

http://www.w3.org/2001/XMLSchema#string

P698

27828943

http://www.w3.org/2001/XMLSchema#string

P932

5634331

http://www.w3.org/2001/XMLSchema#string